The supplement industry is currently navigating a complex regulatory environment, particularly concerning peptides and the evolving definitions of what constitutes a drug versus a dietary supplement. Amidst this debate, a significant trend is emerging: the increasing popularity of injectable forms for many once-oral supplement ingredients. This shift is largely driven by the inherent limitations of oral delivery for certain compounds, such as peptides, which are short chains of amino acids. Their delicate structure often prevents them from surviving the digestive system, necessitating alternative delivery methods. This reality has cemented the needle as the primary, and sometimes only, viable route for these potent compounds.
This reliance on injections might seem counterintuitive in a consumer market where apprehension about needles and self-administered procedures is often cited as a significant barrier. Traditional wisdom suggests that any alternative delivery method – be it capsules, tablets, liquids, or lozenges – holds a distinct advantage in meeting consumer demand for health and wellness products. However, a growing segment of consumers is demonstrating a willingness to embrace "pinning" common supplement ingredients, delivered through pharmaceutical-grade injections.
The GLP-1 class of drugs, such as semaglutide, has been a major catalyst in normalizing injectable treatments. For years, the only option for these compounds was injection, with the anticipation of an oral formulation like Novo Nordisk’s Wegovy in early 2026 underscoring this point. The burgeoning field of peptide therapeutics has further diminished consumer aversion to injections. This trend is amplified by the proliferation of wellness clinics offering intravenous (IV) drips and intramuscular (IM) shots. IV drips, typically lasting around 60 minutes, and IM shots, taking mere seconds, are becoming increasingly accessible and normalized pathways for wellness seekers.
These clinics are often stocked with ingredients familiar to the supplement industry, ranging from essential vitamins and minerals to specialized compounds like Nicotinamide Adenine Dinucleotide (NAD+), glutathione, and phosphatidylcholine. While the regulatory distinction is clear – injections fall under drug classification, demanding stringent manufacturing standards – the rise of supplement-like injections represents a novel and expanding niche sales channel.
The Rise of Injectable Wellness in Clinics
Integrative wellness centers, such as Alive and Well, with locations in Boulder, Colorado, and Austin and Dallas, Texas, are at the forefront of this movement. Nurse-administered IV drips and injections, alongside peptide therapies, are driving significant consumer interest. Claire Lev, General Manager at Alive and Well, notes, "Peptides are definitely a thing. They’re the top curiosity in the clinic. Guests want to dive deeper to understand which peptide does what, and whether or not they’re safe."
Currently, Alive and Well offers walk-in access to two popular peptides: BPC-157, primarily used for muscle and tissue repair, and CJC-Ipamorelin, often sought for weight loss and body composition enhancement. For individuals seeking a more comprehensive peptide regimen, membership options are available. These memberships include advanced biomarker panels, consultations with providers to interpret results, and discounted access to peptides for at-home injection.
Lev observes, "This is becoming more and more common. The weight-loss drugs have normalized at-home injections. We have guests coming in several times a week for vitamin shots, and at that point the shot itself becomes less of an issue." This normalization, accelerated by the widespread adoption of GLP-1 medications, has paved the way for other injectable wellness solutions.
Andrew Shao, Ph.D., senior vice president of regulatory and scientific affairs at Niagen Bioscience, a company offering both oral supplements and pharmaceutical-grade injections of its NAD+ precursor, highlights this broader trend. "Peptides have helped normalize injectable wellness therapies and introduced many consumers to longevity medicine," Shao states. "But they have also accelerated a broader trend. Consumers are increasingly willing to inject almost anything that promises more energy, better skin, faster recovery or healthier aging. The challenge is that innovation has outpaced oversight, leaving many consumers unsure what they are actually being injected with, where the ingredients came from or whether they are backed by meaningful science."
Niagen Bioscience recently launched a telehealth platform, allowing eligible patients to receive prescription-only at-home injection kits directly. "This new Niagen Plus telehealth platform is expanding access to pharmaceutical-grade Niagen to support NAD+ and cellular and tissue health," Shao explains. This initiative exemplifies the blurring lines between supplements and drugs, particularly for ingredients with substantial clinical research backing, like Niagen.
What’s Trending and What’s Not in the Injectable Market
In contrast to branded products like Niagen Plus, many ingredients dispensed through drip clinics are unbranded. Lev comments, "Brands are more of a consumer preference when it comes to supplements. They can see the label, hold the bottle. With injections and IVs, they never see the vials that go into making the bags."
While Tru Niagen, the oral supplement, enjoys strong retail sales as an "upgraded version of NAD+," the clinic is preparing to offer Niagen Plus as an IV and IM shot. Previous NAD+ IV infusions offered at some clinics have been associated with side effects like dizziness and stomach upset, and their administration could take up to three hours. These drawbacks present a significant pain point, driving the shift towards Niagen Plus, even at a higher cost.
"With injectable therapies, quality matters just as much as the research behind the ingredient itself," emphasizes Shao. Both the oral supplement and the injectable version of Niagen are based on the company’s patented nicotinamide riboside (NR) ingredient. However, Niagen Plus utilizes a pharmaceutical-grade ingredient compounded by U.S. FDA-registered 503A and 503B facilities. "In a rapidly expanding category where sourcing and manufacturing can vary significantly, that level of scientific validation and quality control becomes a meaningful differentiator," Shao adds.
A prime example of the current market landscape is Alive and Well’s "Director’s Choice IV," priced at $265. This comprehensive infusion includes vitamin C, magnesium, biotin, zinc, B-complex, glutamine, CoQ10, and a glutathione push, along with an Ultraburn IM Injection. The Ultraburn injection itself contains B12 (methylcobalamin), B1, B2, B6, methionine, inositol, choline, carnitine, B3, and chromium. While this combination is offered as a prescription under medical supervision, it reads remarkably like a potent, multi-faceted nutritional supplement.
It is unsurprising that IV wellness drips are marketed with condition-specific claims that mirror those found in the supplement industry. Drip bags are formulated to address concerns such as energy levels, detoxification, gut health, immunity, and women’s health, alongside traditional uses like hangover remedies and altitude sickness relief.
The Evolving Landscape and Future Outlook
"Healthspan medicine has become more mainstream, creating demand for pharmaceutical-grade, clinically administered and/or provided therapies that are backed by science," states Shao. "As the field continues to evolve, I think we will see greater emphasis on evidence, quality and medical oversight alongside that growth."
Looking ahead, certain ingredients are in high demand. Lev notes, "We do get requests for magnesium. We have it in our bags for IVs, but it can’t be used as an IM shot. It’s one of our bestselling supplements, so having that in an IM shot would be great." The desire to replicate the convenience and efficacy of oral supplements in injectable formats continues to drive innovation.
Not all injectable ventures have achieved widespread success. The Methylene Blue IV bag, for instance, did not gain traction at Alive and Well. Lev explains, "I felt great when I got that IV. Better mood, energy, clarity, but you have to use the whole vial in one day, so you need five IVs to make it worth spiking the vial." Despite promotional efforts, clinic guests have opted for Methylene Blue in a troche form – a small lozenge that dissolves slowly in the mouth – rather than through IV drips, highlighting the importance of delivery method convenience and practicality for consumer adoption.
As the distinctions between supplement and drug-based nutritional solutions continue to blur, the role of telehealth is becoming paramount. The consumer journey often commences with diagnostics and prescriptions from a credentialed healthcare provider, but increasingly concludes with self-administration of injections at home. This evolving model necessitates a careful balance between consumer accessibility and robust medical oversight.
The integration of pharmaceutical-grade ingredients, coupled with scientific validation and quality control, is emerging as a key differentiator in this rapidly expanding market. Consumers are actively seeking tangible benefits, from enhanced energy and improved athletic recovery to anti-aging effects. The injectable wellness trend, propelled by advancements in peptide and NAD+ science and further normalized by blockbuster weight-loss medications, is poised to reshape how individuals approach their health and wellness goals, demanding greater transparency and evidence-based practices from both manufacturers and providers. The future of this sector likely hinges on its ability to navigate the regulatory landscape while consistently delivering safe, effective, and scientifically supported solutions to an increasingly informed consumer base.
